Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026

Moderna (MRNA)

Nasdaq Health Care Biotechnology S&P 500Nasdaq-100
$254.19
+12.73 (+5.27%)
Close of Nov 06, 2026 · end-of-day data
Source: Moderna's 10-K / 10-Q XBRL data on SEC EDGAR · fetched Nov 06, 2026

Revenue, net income & free cash flow

Income statement

fiscal years · USD
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue$108.40M$205.82M$135.07M$60.21M$803.00M$18.47B$19.26B$6.85B$3.24B$1.94B
Cost of revenue——$0$0$8.00M$2.62B$5.42B$4.69B$1.46B$868.00M
Gross profit——$135.07M$60.21M$795.00M$15.85B$13.85B$2.15B$1.77B$1.08B
Research & development$274.72M$410.46M$454.08M$496.00M$1.37B$1.99B$3.29B$4.84B$4.54B$3.13B
Operating income-$223.77M-$269.36M-$413.27M-$546.00M-$763.00M$13.30B$9.42B-$4.24B-$3.94B-$3.07B
Pre-tax income-$215.17M-$256.00M-$384.41M-$515.00M-$744.00M$13.29B$9.57B-$3.94B-$3.61B-$2.77B
Income tax$1.04M-$80.00K$326.00K-$1.00M$3.00M$1.08B$1.21B$772.00M-$46.00M$54.00M
Net income-$216.21M-$255.92M-$384.73M-$514.00M-$747.00M$12.20B$8.36B-$4.71B-$3.56B-$2.82B
EBITDA-$208.66M-$248.82M-$388.40M-$515.00M-$732.00M$13.53B$9.77B-$3.62B-$3.76B-$2.86B
EPS (basic)$-3.79$-4.18$-4.95$-1.55$-1.96$30.31$21.26$-12.33$-9.28$-7.26
EPS (diluted)$-3.79$-4.18$-4.95$-1.55$-1.96$28.29$20.12$-12.33$-9.28$-7.26
Diluted shares60.75M64.50M81.11M331.00M381.00M431.00M416.00M382.00M384.00M389.00M
Gross margin——100.0%100.0%99.0%85.8%71.9%31.5%54.8%55.3%
Operating margin-206.4%-130.9%-306.0%-906.8%-95.0%72.0%48.9%-61.9%-121.9%-158.1%
Net margin-199.5%-124.3%-284.8%-853.7%-93.0%66.1%43.4%-68.8%-110.0%-145.2%

Balance sheet

fiscal years · USD
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash & equivalents$50.08M$134.86M$658.36M$236.00M$2.62B$6.85B$3.21B$2.91B$1.93B$2.60B
Short-term investments—$621.17M$863.06M$867.12M$1.98B$3.88B$6.70B$5.70B$5.10B$3.20B
Receivables—$11.88M$11.69M$5.37M$1.39B$3.17B$1.39B$892.00M$358.00M$184.00M
Inventory———$0$47.00M$1.44B$949.00M$202.00M$117.00M$153.00M
Total current assets—$783.22M$1.56B$1.13B$6.30B$16.07B$13.43B$10.32B$8.10B$6.54B
Goodwill——————$0$52.00M$52.00M$52.00M
Total assets—$1.08B$1.96B$1.59B$7.34B$24.67B$25.86B$18.43B$14.14B$12.34B
Total current liabilities—$191.46M$222.80M$143.12M$4.39B$9.13B$4.92B$3.02B$2.21B$1.99B
Long-term debt————————$0$590.00M
Total debt————————$0$590.00M
Total liabilities—$459.19M$431.91M$414.61M$4.78B$10.52B$6.74B$4.57B$3.24B$3.69B
Shareholders' equity-$334.81M-$551.37M$1.53B$1.18B$2.56B$14.14B$19.12B$13.85B$10.90B$8.65B

Cash flow

fiscal years · USD
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow$66.73M-$331.48M-$330.87M-$459.00M$2.03B$13.62B$4.98B-$3.12B-$3.00B-$1.87B
Capital expenditures$33.14M$58.40M$105.77M$32.00M$68.00M$284.00M$400.00M$707.00M$1.05B$192.00M
Free cash flow$33.59M-$389.88M-$436.63M-$491.00M$1.96B$13.34B$4.58B-$3.83B-$4.05B-$2.06B
Investing cash flow-$648.61M$417.36M-$373.09M-$15.00M-$1.67B-$8.52B-$5.18B$4.21B$1.95B$1.95B
Financing cash flow$472.91M$168.00K$1.23B$52.00M$2.03B-$873.00M-$3.45B-$1.38B$56.00M$593.00M
Share buybacks———$0$0$857.00M$3.33B$1.15B$0$2.00M
Stock-based compensation$39.36M$40.05M$72.56M$81.00M$93.00M$142.00M$226.00M$305.00M$429.00M$483.00M
Depreciation & amortization$15.11M$20.54M$24.86M$31.00M$31.00M$232.00M$348.00M$617.00M$185.00M$211.00M

Quarterly figures are rebuilt from the year-to-date totals companies report — Q4 is the full year minus the first nine months, since no 10-Q is filed for it. Values are as filed; later restatements replace earlier ones. Fiscal years are labelled by the calendar year in which they end.